Ontex Q1 2026 slides: revenue falls 4% amid market softening, outlook held

Ontex reported Q1 2026 revenue of €426.3 million, down 4.0% like-for-like, as volume declines of €21 million and EBITDA margin compression to 9.1% outweighed resilience in adult care. Net debt improved to €550 million, but leverage rose to 3.36x, above the prior 3.29x, and the stock fell 1.92% to €3.00. Management kept full-year 2026 guidance unchanged, targeting 10% adjusted EBITDA growth and leverage below 3.0x, supported by 15% SG&A reduction plans and capacity rationalization.

Analysis

The key signal is not the modest miss; it’s that the company is now forcing a structural fix while operating at the edge of its covenant band. When leverage is above 3x and EBITDA is still being diluted by volume loss, management has far less room to absorb any further baby-care deterioration or FX/raw-material volatility, which means equity becomes a thin residual claim on execution rather than market recovery. That creates a classic setup where the first-order story is “maintained guidance,” but the second-order risk is a future reset if the cost actions lag the sales decline by even one quarter.

The beneficiary set is more nuanced than the headline suggests. Branded diaper and feminine-care players can exploit the weaker private-label backdrop to defend share and potentially hold price, while contract manufacturers tied to discretionary private-label volume are the most exposed to order volatility and plant under-absorption. The announced footprint rationalization also implies some short-term disruption costs before benefits accrue, so suppliers in packaging, transport, and flexible labor may see temporary demand loss, but the bigger medium-term effect is that fixed-cost intensity in this category should come down, lifting the relative competitiveness of larger, more efficient incumbents.

The market is likely underpricing timing risk versus outcome risk. The 10% EBITDA growth target may still be achievable on a full-year basis, but the path matters: if Q2 does not show visible margin recovery, the equity could rerate lower well before any covenant pressure becomes acute. Conversely, if management can convert the SG&A reduction and capacity actions into visible cash generation by late summer, the stock could snap back quickly because the current valuation is already discounting a prolonged trough.

The contrarian view is that the setup may be less about demand collapse and more about a clean-up year in which management finally rightsizes the business. If adult care continues to grow structurally and the baby-care reset stabilizes, then the leverage peak may already be in place, making the current equity weak but not necessarily broken. The real catalyst to watch is not guidance reaffirmation, but evidence that working capital, capex, and restructuring cash outflows are falling faster than EBITDA, which would de-risk the balance sheet meaningfully over the next 2-3 quarters.

Key Decisions for Investors

• Short ONTEX.BR into the next earnings window if Q2 margin recovery is not visible; target 10-15% downside on a guidance-trust reset, with a tight stop on evidence of accelerating cash conversion.
• Buy a small call spread only after management shows measurable SG&A/capacity savings in the next quarter; asymmetry improves if the market starts pricing a 2027 earnings uplift rather than a 2026 miss.
• Pair trade: long a higher-quality hygiene/consumer staples name versus short ONTEX.BR to express a relative-value view on execution quality and balance-sheet resilience over 3-6 months.
• Watch covenant-sensitive credits and suppliers tied to private-label baby-care production; any sign of customer rationalization or order pullbacks would be a fast negative read-through for adjacent packaging and logistics names.
• If leverage drops below 3.1x by late 2026 on real EBITDA improvement rather than debt reduction alone, reassess for a tactical long; until then, treat rallies as fadeable unless cash flow inflects decisively.